Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 2/20 | 0.42 |
| ▸ | MC4R | P32245 | 2/20 | 0.40 |
| ▸ | MC3R | P41968 | 1/20 | 0.40 |
| ▸ | CCKBR | P32239 | 8/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | UGCG | Q16739 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28433679 | 1.00 | PKM (0.45) | PKMTACR1MC4RMC3RCCKBR | |
| SCHEMBL1879075 | 0.78 | CCR1 (0.42) | — | |
| SCHEMBL29823437 | 0.78 | CCR1 (0.42) | — | |
| SCHEMBL28438648 | 0.78 | CCR1 (0.42) | — | |
| SCHEMBL1870607 | 0.76 | CCR3 (0.45) | — | |
| SCHEMBL29823495 | 0.76 | CCR3 (0.45) | — | |
| SCHEMBL5790256 | 0.73 | KMT2A (0.41) | — | |
| SCHEMBL29823683 | 0.72 | CCR3 (0.40) | — | |
| SCHEMBL1886461 | 0.72 | CCR3 (0.40) | — | |
| SCHEMBL1873995 | 0.70 | KMT2A (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025230907-A1 | A CXCR4 ANTAGONIST, A STATS ACTIVATOR, AND/OR AN AGENT THAT INCREASES NITRIC OXIDE CONTENT FOR USE IN METHODS OF IMPROVING NERVE REGENERATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-06 | — | — | WO | disclosed |
| EP-3735412-B1 | COMPOSITIONS AND METHODS FOR THE EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AND TREATMENT OF INHERITED METABOLIC DISORDERS | EDIGENE BIOTECHNOLOGY INC (CN) | 2024-02-21 | — | — | EP | disclosed |
| EP-4308694-A1 | DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS | Magenta Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-115997009-A | Methods and compositions for in vivo transduction of hematopoietic stem and progenitor cells | 美真达治疗公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4143302-A1 | METHODS AND COMPOSITIONS FOR TRANSDUCING HEMATOPOIETIC STEM AND PROGENITOR CELLS IN VIVO | Magenta Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2022197776-A1 | DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS | Magenta Therapeutics, Inc. (US) | 2022-09-22 | — | — | WO | disclosed |
| EP-4051298-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENTOR CELLS | Magenta Therapeutics, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |